The addition of an off-the-shelf pooled stem cell product to a single unit of umbilical cord blood conferred favorable ...

NIKTIMVO® (axatilimab) approved by the Therapeutic Goods Administration (TGA) under Priority Review for the treatment of eligible Australian patients with chronic graft-versus-host disease[2]Australia ...

Novel conditioning regimen improves survival and engraftment in sickle cell transplant patients with low graft versus host ...

A reduced-intensity bone marrow transplant regimen developed by Johns Hopkins physicians provides durable engraftment with ...

Hematopoietic cell transplantation (HCT) is a lifesaving treatment for people diagnosed with fatal blood cancers or other blood disorders. The procedure involves replacing the recipient’s blood ...

Stem cell transplants for acute leukemia using pooled, non-human leukocyte antigen (HLA)-matched cord blood led to near-perfect engraftment and no severe graft-versus-host disease (GVHD) in a small ...

Amandeep Salhotra, MD, of City of Hope National Medical Center in Duarte, California, explores the safety and tolerability of ...

Cellenkos receives US FDA clearance to initiate phase 1b/2a trial of CK0802 in steroid-refractory graft-versus-host disease: Houston Thursday, May 7, 2026, 18:00 Hrs [IST] Cellenk ...

On the heels of FDA’s clearance, the company plans to begin a Phase Ib/IIa trial evaluating CK0802 in patients who have ...

Please provide your email address to receive an email when new articles are posted on . Over 65% of patient-reported treatment responses agreed with clinicians’ evaluations, whereas 34.4% did not.

Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Jakafi XR™ (ruxolitinib) ...